Neurocrine Biosciences Inc

NBIX

132.420USD

+1.290+0.98%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

Neurocrine Biosciences Inc's Score

Industry at a Glance

Industry Ranking

6 / 157

Overall Ranking

33 / 4546

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Neurocrine Biosciences Inc Highlights

StrengthsRisks

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 51.58% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.86B.

Undervalued

The company’s latest PE is 27.53, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 100.61M shares, decreasing 4.94% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.93K shares of this stock.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

176.268

Target Price

+37.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Neurocrine Biosciences Inc is 9.22, ranking 9 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 805.50M, representing a year-over-year increase of 28.33%, while its net profit experienced a year-over-year increase of 49.08%.

Score

Industry at a Glance

Previous score

9.22

Change

0



Financials

8.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.71

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Neurocrine Biosciences Inc is 5.24, ranking 149 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 27.53, which is 461.85% below the recent high of 154.68 and 7.04% above the recent low of 25.59.

Score

Industry at a Glance

Previous score

5.24

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Neurocrine Biosciences Inc is 8.47, ranking 32 out of 157 in the Pharmaceuticals industry. The average price target is 179.00, with a high of 203.00 and a low of 146.00.

Score

Industry at a Glance

Previous score

8.47

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Neurocrine Biosciences Inc is 9.09, ranking 12 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 136.46 and the support level at 126.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.74

Change

0.35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Neurocrine Biosciences Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 100.90%, representing a quarter-over-quarter decrease of 0.43%. The largest institutional shareholder is The Vanguard, holding a total of 9.66M shares, representing 9.62% of shares outstanding, with 3.82% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

9.88M

-2.00%

The Vanguard Group, Inc.

Star Investors

9.66M

-1.05%

Dodge & Cox

Star Investors

5.56M

-0.18%

JP Morgan Asset Management

4.03M

+13.10%

State Street Investment Management (US)

4.35M

-2.73%

AQR Capital Management, LLC

2.77M

+83.68%

Renaissance Technologies LLC

Star Investors

2.42M

+2.19%

Geode Capital Management, L.L.C.

2.02M

+3.35%

T. Rowe Price Associates, Inc.

Star Investors

2.78M

-7.53%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neurocrine Biosciences Inc is 8.12, ranking 28 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Neurocrine Biosciences Inc

NBIX

8.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment